Works matching IS 21641153 AND DT 2023 AND VI 13 AND IP 3

Results: 18

New Oncology Drugs, New Indications, and New Formulations Approved by the FDA.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 167
Publication type:: Article

Preclinical and Early Clinical Data Show Promising Antitumor Activity With the HER2 Inhibitor ZN-1041 in Patients With Breast Cancer and Brain Metastases.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 166
Publication type:: Article

Dalpiciclib Plus Pyrotinib and Endocrine Therapy Shows Promising Antitumor Activity in ER-Positive, HER2-Positive Metastatic Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 165
Publication type:: Article

Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab to Find Chemotherapy-Free Treatment Combination Regimens for HER2-Positive Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 164
Publication type:: Article

Strong Antitumor Activity With Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 163
Publication type:: Article

Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastases in Patients With Triple-Negative or HER2-Positive Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 162
Publication type:: Article

Neratinib Plus Trastuzumab Emtansine in Patients With HER2-Positive Breast Cancer and Molecular Residual Disease.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 161
Publication type:: Article

Dalpiciclib Plus Pyrotinib Prolongs Survival in Patients With HER2-Positive Advanced Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 160
Publication type:: Article

Inetetamab Plus Camrelizumab and Utidelone Safe and Effective in Patients With HER2-Positive Metastatic Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 159
Publication type:: Article

Prolonged Effectiveness With Tucatinib Plus Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 158
Publication type:: Article

Zanidatamab Plus Docetaxel Shows Promising Antitumor Activity in Advanced HER2-Positive Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 157
Publication type:: Article

Successful Extended At-Home Olaparib Desensitization After a Hypersensitivity Reaction: A Case Report.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 153

By:

Jia, Lily Y.;
Sendrowski, Brendan;
Lax, Timothy;
Shea, Meghan

Publication type:

Article

Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist-Based Intravenous Chemotherapy Education and Follow-Up Program.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 146

By:

Lee, Grant W.;
Chundamala, Joseen J.;
Monahan, Kerri L.;
Cho, Judy J.;
Berry, Lydia J.;
Cambareri, Christine G.

Publication type:

Article

Stopping Oral Chemotherapy Agents With a High Bleeding Risk Before and After Minor Surgical Procedures.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 140

By:

Marjoncu, Dennis;
Carmichael, Jenna;
Andrick, Benjamin J.;
Oxenberg, Jacqueline

Publication type:

Article

Retrospective Evaluation of Initial Empiric Double Coverage With Tobramycin in Adult Patients With Febrile Neutropenia.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 133

By:

Clemmons, Amber B.;
Shelley, Rachel;
Chittavong, Vayou;
Huimin Hu;
Xianyan Chen;
Eudy, Joshua;
Chao, Andrew;
Anderson, Daniel T.

Publication type:

Article

Incidence of Infusion-Related Reactions With Pertuzumab and Ado-Trastuzumab Emtansine: A Retrospective Study.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 128

By:

Smith, Sara Moran

Publication type:

Article

To the Editor.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 126

By:

Hamadeh, Issam S.;
Atrash, Shebli

Publication type:

Article

JHOP Editorial Board Member, Readers, and Author Interact: Optimizing the Administration of Daratumumab.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 125

By:

Soefje, Scott A.

Publication type:

Article